The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer.

ABSTRACT:

Background

The study investigated the resistant pattern and clinical outcomes of epidermal growth factor receptor (EGFR) exon 19 deletion (19del) subtypes to tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC).

Methods

Two hundred eight treatment naive NSCLC patients detected as EGFR 19del using amplification-refractory mutation system (ARMS) were included. DNA sequencing was used to detect the subtypes. Clinicopathological features as well as patients' outcomes treated with first-line EGFR-TKIs were analyzed.

Results

Thirteen EGFR 19del subtypes were confirmed in 181 samples (87.0%). Among these, delE746_A750 was the most frequent subtype (130/181, 71.8%). delE746_A750 and deletions starting from E746 were frequently found in

SUBMITTER: Zhao C 

PROVIDER: S-EPMC7481579 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature